Treatment of Macular Degeneration
OwnerFrances Margaret Richards, Alan Geoffrey Roachinventors
Life of this patent
Estimating the term…
Abstract
An agent having progesterone antagonist properties may be used to treat eye conditions associated with pathological blood vessel formation, for example age-related macular degeneration, choroidal neovascularisation, retinal neovascularisation or corneal neovascularisation. The agent may be mifepristone.
Claims21
A method for treating a condition associated with blood vessel formation wherein said method comprises administering to a subject in need of such treatment an agent having progesterone antagonist properties.
5-7. (canceled)
A method for treating wet AMD wherein said method comprises administering, to a subject in need of such treatment, mifepristone (RU486), or a metabolite or pharmaceutically acceptable derivative thereof.
A pharmaceutical composition for topical administration to the eye comprising mifepristone (RU486), or a metabolite or pharmaceutically acceptable derivative thereof.
22-29. (canceled)
Dependencies are inferred from the claim text.